Aspirin / carisoprodol Pregnancy and Breastfeeding Warnings

Brand names: Carisoprodol Compound, Soma Compound

Aspirin / carisoprodol Pregnancy Warnings

Use is not recommended unless clearly needed.

US FDA pregnancy category D

Comments:
-Aspirin should be avoided after 30 weeks gestation as it may lead to premature closure of the fetal ductus arteriosus.

There are no animal reproduction studies with this combination product. Animal studies with carisoprodol have shown effects on fetal growth and postnatal survival. Salicylic products have shown to be teratogenic and embryocidal in rodents at doses considered much greater than usual therapeutic human doses. Aspirin use within 1 week of delivery or during labor may prolong delivery or lead to excessive blood loss in the mother or baby. There are no controlled data in human pregnancy.

US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Aspirin / carisoprodol Breastfeeding Warnings

Breastfeeding is not recommended

Excreted into human milk: Yes (aspirin); Yes (carisoprodol)

Comment:
-Most experts recommend against breastfeeding while taking aspirin, especially when using higher doses.

Aspirin is excreted as salicylic acid in breastmilk. Higher doses of aspirin appear to result in disproportionately higher milk levels. Reye's syndrome is associated with aspirin administration in infants with viral illnesses, however the risk from breastfeeding is unknown. Maternal use of carisoprodol may lead to reduced or less effective infant feeding due to sedation and/or decreased milk production. Alternative agents are recommended.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer